Prostate cancer: PSA as an intermediate end point in clinical trials - PubMed (original) (raw)

Prostate cancer: PSA as an intermediate end point in clinical trials

Gerhardt Attard et al. Nat Rev Urol. 2009 Sep.

No abstract available

PubMed Disclaimer

Similar articles

• Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
  Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH; European Organisation for Research and Treatment of Cancer; Limburgs Universitair Centrum; AstraZeneca Pharmaceuticals. Collette L, et al. J Clin Oncol. 2005 Sep 1;23(25):6139-48. doi: 10.1200/JCO.2005.08.156. J Clin Oncol. 2005. PMID: 16135480
• Prostate cancer: PSA update--no change yet.
  Phillips R. Phillips R. Nat Rev Urol. 2014 Sep;11(9):483. doi: 10.1038/nrurol.2014.210. Epub 2014 Aug 19. Nat Rev Urol. 2014. PMID: 25134834 No abstract available.
• Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.
  Collette L, Burzykowski T, Schröder FH. Collette L, et al. Eur J Cancer. 2006 Jul;42(10):1344-50. doi: 10.1016/j.ejca.2006.02.011. Epub 2006 May 30. Eur J Cancer. 2006. PMID: 16730974 Review.
• PSA kinetics and surrogacy: ready for prime time?
  Freedland SJ. Freedland SJ. Lancet Oncol. 2008 Nov;9(11):1025-6. doi: 10.1016/S1470-2045(08)70267-5. Lancet Oncol. 2008. PMID: 19012853 No abstract available.
• Complexed prostate-specific antigen improvement in detecting prostate cancer.
  Okihara K, Babaian RJ. Okihara K, et al. Curr Urol Rep. 2001 Jun;2(3):253-8. doi: 10.1007/s11934-001-0088-7. Curr Urol Rep. 2001. PMID: 12084274 Review.

Cited by

• Translating cancer research into targeted therapeutics.
  de Bono JS, Ashworth A. de Bono JS, et al. Nature. 2010 Sep 30;467(7315):543-9. doi: 10.1038/nature09339. Nature. 2010. PMID: 20882008
• Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies.
  Huber F, Montani M, Sulser T, Jaggi R, Wild P, Moch H, Gevensleben H, Schmid M, Wyder S, Kristiansen G. Huber F, et al. Br J Cancer. 2015 Jan 6;112(1):140-8. doi: 10.1038/bjc.2014.588. Epub 2014 Nov 25. Br J Cancer. 2015. PMID: 25422912 Free PMC article.
• Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.
  Weier C, Haffner MC, Mosbruger T, Esopi DM, Hicks J, Zheng Q, Fedor H, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Weier C, et al. J Pathol. 2013 Jun;230(2):174-83. doi: 10.1002/path.4186. J Pathol. 2013. PMID: 23447416 Free PMC article.
• The changing therapeutic landscape of castration-resistant prostate cancer.
  Yap TA, Zivi A, Omlin A, de Bono JS. Yap TA, et al. Nat Rev Clin Oncol. 2011 Aug 9;8(10):597-610. doi: 10.1038/nrclinonc.2011.117. Nat Rev Clin Oncol. 2011. PMID: 21826082 Review.
• Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
  Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J. Ruggiero A, et al. J Nucl Med. 2011 Oct;52(10):1608-15. doi: 10.2967/jnumed.111.092098. Epub 2011 Sep 9. J Nucl Med. 2011. PMID: 21908391 Free PMC article.

References

1. 1. Clin Cancer Res. 2008 Oct 1;14(19):6302-9 - PubMed
2. 1. J Natl Cancer Inst. 2006 Apr 19;98(8):516-21 - PubMed
3. 1. J Clin Oncol. 2009 Jun 10;27(17):2766-71 - PubMed
4. 1. J Clin Oncol. 2005 Sep 1;23(25):6139-48 - PubMed
5. 1. J Clin Oncol. 2009 May 20;27(15):2450-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal